Skip to main content

Advertisement

Table 1 Clinicopathological features of breast cancer patients

From: Diagnostic and prognostic microRNAs in the serum of breast cancer patients measured by droplet digital PCR

Characteristics Cohort A (n = 28) Cohort B (n = 59)
Age Mean age (SD) 65.3 (±14.4) 56.7 (±10.4)
Range 33–91 34–81
Menopausal status Pre 3 (11 %) 14 (24 %)
Peri 7 (25 %) 1 (2 %)
Post 18 (64 %) 44 (75 %)
Histological subtype Ductal 21 (75 %) 48 (81 %)
Lobular 4 (14 %) 4 (7 %)
Tubular 1 (4 %) 1 (2 %)
Other 2 (7 %) 6 (10 %)
Tumor size (pT) pT1 21 (75 %) 28 (47 %)
pT2 7 (25 %) 27 (46 %)
pT3 0 4 (7 %)
Lymph node involvement (pN) pN0 21 (75 %) 35 (59 %)
pN1 6 (21 %) 16 (27 %)
pN2 0 6 (10 %)
pN3 1 (4 %) 1 (2 %)
pNx 0 1 (2 %)
Metastasis (cM)a M0 28 (100 %) 57 (97 %)
M1 0 2 (3 %)
Stage I 16 (57 %) 24 (41 %)
II 11 (39 %) 24 (41 %)
III 1 (4 %) 9 (15 %)
IV 0 2 (3 %)
Grade I 5 (18 %) 11 (19 %)
II 18 (64 %) 14 (24 %)
III 5 (18 %) 34 (58 %)
Estrogen receptor Positive 26 (93 %) 41 (69 %)
Negative 2 (7 %) 16 (27 %)
Missing 0 2 (3 %)
Progesterone receptor Positive 19 (68 %) 35 (59 %)
Negative 9 (21 %) 22 (37 %)
Missing 0 2 (3 %)
HER2/neu receptor Positive 3 (11 %) 11 (19 %)
Negative 25 (89 %) 44 (75 %)
Uncertain 0 1 (2 %)
Missing 0 3 (5 %)
Triple negative ER-/PR-/HER2- 1 (4 %) 9 (15 %)
  1. a cM Clinical evidence of metastasis
  2. HER2/neu human epidermal growth factor receptor 2, ER Estrogen receptor, PR Progesterone receptor